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This study aimed to describe the population at risk of severe COVID-19 due to underlying health 
conditions across the United Kingdom in 2019. 
Methods 
We used anonymised electronic health records from the Clinical Practice Research Datalink GOLD to 
describe the point prevalence on 5 March 2019 of the at-risk population following national guidance. 
Prevalence for any risk condition and for each individual condition is given overall and stratified by 
age and region. We repeated the analysis on 5 March 2014 for full regional representation and to 
describe prevalence of underlying health conditions in pregnancy. We additionally described the 
population of cancer survivors, and assessed the value of linked secondary care records for 
ascertaining COVID-19 at-risk status. 
Findings 
On 5 March 2019, 24·4% of the UK population were at risk due to a record of at least one underlying 
health condition, including 8·3% of school-aged children, 19·6% of working-aged adults, and 66·2% 
of individuals aged 70 years or more. 7·1% of the population had multimorbidity. The size of the at-
risk population was stable over time comparing 2014 to 2019, despite increases in chronic liver 
disease and diabetes and decreases in chronic kidney disease and current asthma. Separately, 1·6% 
of the population had a new diagnosis of cancer in the past five years. 
Interpretation 
The population at risk of severe COVID-19 (aged ≥70 years, or with an underlying health condition) 
comprises 18.5 million individuals in the UK, including a considerable proportion of school-aged and 
working-aged individuals. 
Funding  
NIHR HPRU in Immunisation 
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Research in context 
Evidence before this study 
We searched Pubmed for peer-reviewed articles, preprints, and research reports on the size and 
distribution of the population at risk of severe COVID. We used the terms (1) risk factor or co-
morbidity or similar (2) COVID or SARS or similar and (3) prevalence to search for studies aiming to 
quantify the COVID-19 at-risk UK population published in the previous year to 19 July 2020, with no 
language restrictions. We found one study which modelled prevalence of risk factors based on the 
Global Burden of Disease (which included the UK) and one study which estimated that 8.4 million 
individuals aged ≥30 years in the UK were at risk based on prevalence of a subset of relevant 
conditions in England. There were no studies which described the complete COVID-19 at-risk 
population across the UK. 
Added value of this study 
We used a large, nationally-representative dataset based on electronic health records to estimate 
prevalence of increased risk of severe COVID-19 across the United Kingdom, including all conditions 
in national guidance. We stratified by age, sex and region to enable regionally-tailored prediction of 
COVID-19-related healthcare burden and interventions to reduce transmission of infection, and 
planning and modelling of vaccination of the at-risk population. We also quantified the value of 
linked secondary care records to supplement primary care records. 
Implications of all the available evidence 
Individuals at moderate or high risk of severe COVID-19 according to current national guidance (aged 
≥70 years, or with a specified underlying health condition) comprise 18·5 million individuals in the 
United Kingdom, rather than the 8.43 million previously estimated.   
The 8·3% of school-aged children and 19·6% of working-aged adults considered at-risk according to 
national guidance emphasises the need to consider younger at-risk individuals in shielding policies 
and when re-opening schools and workplaces, but also supports prioritising vaccination based on 
age and condition-specific mortality risk, rather than targeting all individuals with underlying 
conditions, who form a large population even among younger age groups. 
Among individuals aged ≥70 years, 66·2% had at least one underlying health condition, suggesting an 
age-targeted approach to vaccination may efficiently target individuals at risk of severe COVID-19.  
These national estimates broadly support the use of Global Burden of Disease modelled estimates 
and age-targeted vaccination strategies in other countries. 
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People with underlying health conditions account for the majority of COVID-19-related hospital and 
intensive care admissions, and are at increased risk of death from COVID-19 compared to the 
general population of the same age.1-4 Prevalence of many conditions increases with age, which is 
also an independent risk factor for COVID-19 mortality.3, 4 
Characterising the population at risk of severe COVID-19 is vital for effective policy and planning in 
response to the COVID-19 pandemic.5 Age- and region-specific prevalence of at-risk groups are key 
to predicting mortality and managing pressure on hospital inpatient and intensive care services 
across the country. Numbers of school-aged children and working-aged adults at risk are important 
for re-opening local schools and workplaces. Vaccination planning requires at-risk population size for 
vaccine numbers, and age and regional distribution for modelling impact on regional transmission, 
since vaccine response typically decreases with older age.6  
Modelling based on the Global Burden of Disease (GBD) study suggests that approximately one in 
five individuals worldwide have a health condition that increases risk of COVID-19.7 National 
prevalence studies of COVID-19 at-risk groups are rare. Large household surveys suggest that a third 
of adults in the United States, and between a third and a half of adults in Brazil, have at least one risk 
factor for COVID-19 (based on age ≥65 years, or underlying health conditions for younger adults).8, 9 
A previous study estimated that at least 8.4 million individuals in the UK were at risk, but included 
only a subset of relevant health conditions.10 Universal healthcare with an electronic health records 
system offers an opportunity for precise and representative estimation of at-risk prevalence in the 
UK which may aid in interpretation of GBD-based estimates elsewhere, and support UK policy. 
This study aimed to quantify the size, composition, and distribution of the population at risk of 
severe COVID-19 across the UK in March 2019, using electronic health records to define at-risk 
status based on all underlying conditions in national guidance.  
Methods 
Data sources  
We conducted a point prevalence study among the UK general population using the Clinical Practice 
Research Datalink (CPRD) GOLD dataset, an anonymised sample of electronic health records from 
primary care practices across the UK.11 The dataset includes diagnoses recorded using Read codes, 
primary care prescribing, and results of tests ordered in primary care. Data validity has been shown 
to be high.12 
Secondary care (hospital) data linkage is available for approximately 75% of CPRD GOLD-registered 
individuals in England, based on practice-level consent. For patients admitted to hospital, the 
Hospital Episode Statistics Admitted Patient Care dataset records diagnoses using International 
Classification of Diseases ICD-10 codes, and procedures such as chemotherapy using Classification of 
Interventions and Procedures OPCS-4 codes.13  
The CPRD Pregnancy Register uses validated algorithms, combining information across the primary 
care record such as antenatal scans, expected delivery dates, and deliveries, terminations and 
miscarriage records, to date and characterise pregnancies in CPRD GOLD.14  
Index dates  
Our primary analysis index date was 5 March 2019 for up-to-date national prevalence estimates. 
CPRD GOLD coverage peaked in 2014, when it included approximately 7% of the UK population: by 
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2019 the dataset was smaller and did not cover all regions in England.  As a secondary analysis, point 
prevalence estimates were repeated for 5 March 2014 for greater power and full regional 
representation across England. 
Pregnancy was described for the index date of 5 March 2014 only, not 5 March 2019, since the latest 
Pregnancy Register update was in February 2018. 
Study population  
The study population comprised individuals aged 2–100 years active in CPRD GOLD, with at least one 
year’s prior registration to allow recording of underlying conditions.15 Eligibility started on the latest 
of: 1 January 2019, second birthday, a year after registration, or practice meeting CPRD quality 
standards. Eligibility ended at the earliest of: 5 March 2019, hundredth birthday, death, leaving the 
practice, or last data collection from the practice. Individuals with any time eligible between 1 
January and 5 March were included in the main analysis of point prevalence on 5 March to increase 
study power, with a sensitivity analysis limited to individuals active in the dataset on 5 March 2019. 
For pregnancy, the study population comprised women aged 11–49 years. As pregnancy is transient, 
women were required to be active in the dataset on 5 March 2014, rather than any time between 1 
January and 5 March 2014. 
Definition of at-risk population  
In national guidance, all individuals aged ≥70 years are considered at moderate risk (Box 1).1 Since 
age-specific population estimates are readily available, the primary analysis for this study defined at-
risk status based on underlying health conditions alone, rather than age. An additional analysis 
estimated the size of the at-risk population including all individuals aged ≥70 years. 
We defined the COVID-19 at-risk population as individuals with at least one underlying health 
condition conferring moderate or high risk of severe COVID-19 according to national guidance (Box 
1). Namely: any history of chronic respiratory disease (excluding asthma), heart disease, kidney 
disease, neurological conditions such as multiple sclerosis, diabetes mellitus; or current asthma, 
severe obesity, or immunosuppression; assessed on the index date.1  
Underlying conditions were defined using diagnoses, height and weight measurements, test results, 
and prescriptions recorded in primary care for the main analysis. Pregnancy status was ascertained 
from the CPRD Pregnancy Register (Supplementary Table 1). Individuals with no recorded body 
mass index were included in the analysis, categorised as having no evidence of severe obesity. For 
analysis using linked secondary care data, diagnoses and procedures recorded in secondary care 
were additionally ascertained from ICD-10 and OCPS-4 codes respectively. 
Cancer survivors have an increased risk of COVID-19 mortality but non-haematological cancer 
survivors are only included in current COVID-19 guidance if receiving immunosuppressing treatment 
(Box 1).3 Separately to the study at-risk definition we described prevalence of any new cancer 
diagnosis in the past one and five years.16  
Statistical Analysis 
Point prevalence estimates of the at-risk population and each underlying condition on 5 March 2019 
were calculated per 100,000 with binomial exact 95% confidence intervals, for each nation in the UK.  
The at-risk population prevalence was stratified by sex and age, categorised in 5-year bands except 
2–9 years and 90–99 years. Prevalence estimates for the at-risk population and each condition were 
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stratified by age and region, separately and in combination. Prevalence values with fewer than five 
individuals were suppressed to preserve confidentiality. 
For additional analysis estimating the size of the at-risk population including all individuals aged ≥70 
years, the at-risk prevalence among individuals aged 2–69 years was age-standardised in 5-year 
bands, and added to the population aged ≥70 years, using mid-2019 national population estimates.17 
Comparison of prevalence in 2014 to 2019 was stratified by region to account for the change in 
regional representation of the dataset over time.  
The point prevalence of pregnancy and underlying health conditions was estimated among women 
aged 11-49 years on 5 March 2014. 
Prevalence estimates with and without linked secondary care records were compared among 
individuals at practices in England which had consented to data linkage.  
Sensitivity analyses 
CPRD GOLD was nationally representative by age and sex in March 2011.11 To update this 
assessment, the 2019 study population was compared to mid-2019 national population estimates, 
and 2019 at-risk prevalence estimates directly age-standardised in five-year bands using mid-2019 
population estimates for each nation.17  
The main analysis included individuals active in the dataset at any point between 1 January and 5 
March 2019. Individuals who left CPRD between 1 January and 5 March would not subsequently 
have had new diagnoses recorded, which could underestimate point prevalence on 5 March. As a 
sensitivity analysis, at-risk prevalence was estimated restricted to individuals active in CPRD on 5 
March 2019. 
All analysis was conducted using STATA 16 MP. 
Ethics approval 
Approval was received from the Independent Scientific Advisory Committee of the Medicines and 
Healthcare Products Regulatory Agency (ISAC number: 20_062A) and the Ethics Committee of the 
London School of Hygiene and Tropical Medicine (reference 21851). The ISAC protocol was made 
available to reviewers. 
Role of the funding source 
The study funder had no role in study design; in the collection, analysis, and interpretation of data; 
in the writing of the report; nor in the decision to submit the paper for publication.  
Results 
Characteristics of the study population  
The 2019 study population included 2,706,053 individuals: 990,939 (36·6%) in England, 801,352 in 
Scotland, 708,670 in Wales and 205,092 in Northern Ireland (Table 1). Approximately half (50·2%) 
were female. The study included 359,412 individuals (13·3%) aged ≥70 years. There was some over-
representation of 40–59-year-olds compared to mid-2019 national population estimates for all four 
countries (Figure 1).  
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In 2014, the dataset included 4,730,254 individuals: 2,980,402 (63·0%) in England, 810,169 (17·1%) 
in Scotland, 730,563 (15·4%) in Wales and 209,120 (4·4%) in Northern Ireland (Supplementary Table 
2). Age and sex distributions were similar to 2019, with 50·3% female and 12·7% aged ≥70 years.  
COVID-19 at-risk population  
On 5 March 2019, 24·4% (95% CI 24·4–24·5) of the study population were at risk of severe COVID-19 
due to underlying health conditions. National at-risk prevalence ranged from 22·6% in England to 
26·5% in Wales (Table 1).  
In a secondary analysis, the number of at-risk individuals based on current guidance including all 
individuals aged ≥70 years was estimated at 18.5 million across the UK, of whom 9·53 million (95% CI 
9·52–9·53) were aged <70 years (Table 2). 
Composition by underlying health conditions 
The commonest conditions across the UK were chronic kidney disease (7·2%), diabetes mellitus 
(7·1%), asthma (6·5%) and chronic heart disease (4·5%). Prevalence of each condition varied 
nationally, with chronic liver disease notably commoner in Scotland (Table 1). Multimorbidity was 
common, ranging from 6·2% in England to 7·9% in Northern Ireland: 7·1% across the UK.  
Variation by age  
The proportion of at-risk individuals increased gradually with age from 5·1% of children aged 2–9 
years to a peak at 79·4% of those aged 85–89 years in England before declining at older ages (Figure 
2). Similar age distributions were seen in each nation, and for each condition except current asthma, 
which peaked at age 10–14 years (Figure 2).  
The at-risk population comprised 18·1% of individuals aged <70 years (including 8·3% of school-aged 
children and 19·6% of working aged adults) and 66·2% of individuals aged ≥70 years across the UK 
(Table 1).  
Variation by sex 
Overall, a higher proportion of women than men were at risk (Table 1), but the association varied 
with age, and men were more likely than women to be at risk from age 55 years upwards (Figure 3, 
Supplementary Table 3). 
Variation by region 
No individuals from the North East or East Midlands regions of England were included in 2019, 
whereas all regions were represented in 2014. London had the lowest proportion of the population 
considered at risk in both 2014 and 2019 (Figure 4). The East of England, South Central and South 
East also had lower prevalence of at-risk individuals than Midlands or Northern regions in both 2014 
and 2019. Regional patterns varied between underlying conditions (Supplementary Figure 1).  
Prevalence estimates of the at-risk population and each condition stratified by age and region 
(separately and combined) on 5 March 2014 and 2019 are here: 
https://doi.org/10.17037/DATA.00001833  
Differences between 2014 and 2019 prevalence estimates 
Compared to 2014, at-risk prevalence estimates in 2019 were 0·8% higher in Northern Ireland but 
lower in Scotland (-0·5%), Wales (-0·8%), and England (-1·3%). When stratified by region within 
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England (Figure 4), at-risk prevalence increased from 2014 to 2019 for Yorkshire and the Humber 
and the West Midlands, and decreased in all other regions (excluding the North East and East 
Midlands, which were unavailable in the 2019 dataset), but no changes exceeded 1·9% difference. 
For underlying conditions, absolute changes in UK prevalence estimates from 2014 to 2019 ranged 
from a -0·9% decrease in chronic kidney disease to a 0·7% increase in diabetes mellitus 
(Supplementary Figure 1). The biggest relative increases were for chronic liver disease (+32·3% from 
2014 to 2019), diabetes (+11·5%) and chronic respiratory disease other than asthma (+11·4%). The 
largest relative falls were for chronic kidney disease (-10·6%) and current asthma (-6·0%). 
Cancer survivors 
On 5 March 2019, 0·4% of the UK had incident cancer recorded within the previous year and 1·6% 
within the previous five years (Table 1). 
Pregnancy  
Among women aged 11–49 years on 5 March 2014, 2·1% were pregnant, of whom 12·9% had a 
recorded health condition, compared to 14·5% of non-pregnant women (Table 3).  
Linked secondary care records 
At-risk prevalence based on standalone primary care records was similar among individuals with and 
without eligibility for data linkage. Linked secondary care records increased the estimated 
prevalence of the at-risk population in England by 1·8% in both 2014 and 2019. The increase was 
greater among individuals <70 years than those ≥70 years.  
For underlying conditions, the greatest absolute changes in prevalence estimates were for 
multimorbidity, which increased from 6·5% to 7·6% in 2019, and chronic heart disease, which 
increased from 4·0% to 5·3%. The greatest relative increase was for chronic liver disease, which 
nearly doubled from 0·27% to 0·53% (Table 4).  
Sensitivity analyses 
Age-standardisation did not alter 2019 at-risk prevalence estimates (not presented).  When the 
study population was restricted to individuals active on 5 March 2019, at-risk prevalence estimates 
fell by less than 1% (Supplementary Table 4). 
Discussion 
This paper describes the size and distribution of the population at risk of severe COVID-19 based on 
clinical records from a large, nationally representative cohort across the UK.  
On 5 March 2019, 24·4% of the UK population were at higher risk than others of the same age due to 
underlying health conditions, including 8·3% of school-aged children, 19·6% of working-aged adults, 
and 66·2% of individuals aged ≥70 years. The commonest conditions were chronic kidney disease, 
diabetes and asthma. Multimorbidity was common at 7·1%. The size and regional distribution of the 
at-risk population was similar in 2014 and 2019, with lower prevalence in London and the South of 
England than Midlands or Northern regions. Separately, the 1·6% of the study population with a new 
diagnosis of cancer within the previous five years may also be at increased risk of severe COVID-19.3  
Including all individuals aged ≥70 years, 18·5 million individuals in the UK would be considered 
moderate or high risk under current national guidance.1 This is higher than a previous estimate of 
8.4 million comprising 7·2% of men and 7·5% of women aged 30–69 years, and 33% of men and 29% 
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of women aged ≥70 years.10 Our estimates include additional conditions to cover the full national 
guidance.1 There were also differences in ascertainment: for example, our diabetes prevalence 
estimate for ages 30–69 in England was 7·0%, compared to 2·2% in the previous study10 and 6·9% in 
the national Quality Outcomes Framework (QOF).18 This may be due to increases in diagnoses and 
recording of diabetes over time in our more recent study period of March 2019 (rather than 1997–
2017).10 
Our at-risk prevalence estimates were slightly lower than GBD-based estimates that 29·1% of the UK 
population had at least one underlying health condition increasing COVID-19 risk, or 28·1% when 
restricted to the same set of conditions (by excluding cancers causing indirect immunosuppression 
and tuberculosis from GBD-based estimates).7 This did not appear to be due to under-estimation of 
clustering due to multimorbidity in the GBD-based study, as the 9·2% multimorbidity prevalence 
modelled was higher than we observed even when using linked secondary care records. The 
difference was greatest among older age groups, and our finding that 19·6% of working-aged adults 
(19–65 years) were at risk is broadly comparable to the GBD-based estimate (for the same 
conditions) of 22·8% among those aged 15–64 years.7  
Our prevalence estimates are in line with national QOF diabetes and cancer monitoring, slightly 
higher than the more narrowly defined QOF chronic heart disease estimates,18 and consistent with 
previous UK studies of chronic kidney disease and asthma.19, 20 The five-year trends of increasing 
diabetes and decreasing asthma prevalence are consistent with directions of change in a previous 
study of asthma,19 and QOF, although 2014 QOF diabetes prevalence was slightly higher at 6·2% in 
2013/14.18 
Linked secondary care records in England increased the estimated size of the at-risk population only 
modestly, but the estimated prevalence of chronic liver disease in 2019 nearly doubled from 0·27% 
to 0·53%, and multimorbidity and chronic heart disease prevalence also increased. Our chronic liver 
disease prevalence estimate in England of 529/100,000 when supplemented with secondary care 
data is more consistent with previous national estimates of approximately 600/100,000 for the UK 
than our lower estimate using primary care data alone.21 Several studies of the associations between 
underlying health conditions and COVID-19 outcomes in England have used standalone primary care 
records to characterise underlying health conditions.4, 16 Such studies may under-ascertain chronic 
liver disease, heart disease and multimorbidity, and thus underestimate associations of these 
conditions with COVID-19 outcomes. If the risk of severe COVID-19 differs between underlying 
health conditions, then their differential under-ascertainment in primary health records may bias 
estimates of associations of underlying health conditions with COVID-19 outcomes.  
Among women who were pregnant on 5 March 2014, 12·9% were at risk due to an underlying health 
condition, compared to a third of the pregnant women admitted to hospital with COVID-19.22 While 
the pregnancy register has high sensitivity for livebirths, pregnancy losses may be under-recorded.14 
The 2·1% point prevalence estimate of pregnancy is perhaps low compared to a survey in which 
591/5686 (10%) of women aged 16-44 years in Britain reported a pregnancy ending in the previous 
year, although these are not easily comparable.23 Caution is required in applying historical pregnancy 
estimates, as COVID-19 may affect family planning.  
Strengths and limitations 
To our knowledge, these are the first prevalence estimates of the full population at risk of severe 
COVID-19 across the UK according to national guidelines. Strengths include the large, nationally 
representative cohort, risk group definitions with detailed ascertainment tailored to risk of COVID-
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19, and quantification of the value of linked secondary care records. To support policy and planning 
flexibly as evidence of the associations of different underlying conditions with COVID-19 outcomes 
evolves, we provide age- and region- stratified prevalence for each underlying condition separately, 
including separating asthma from other respiratory conditions.16, 24  
A key limitation is that UK-wide estimates rely on primary care records, which may miss undiagnosed 
conditions and under-ascertain conditions diagnosed in secondary care. Our analysis including linked 
secondary care records in England suggests that estimates of the overall size of the at-risk 
population are robust, but that the prevalence of multimorbidity, chronic heart disease and liver 
disease may be underestimated from primary care records. There is likely under-ascertainment of 
immunosuppressing cancer treatments even using secondary care records, which could be on a scale 
similar to the 1·6% of the population newly diagnosed with cancer within the previous year. Second, 
the 2019 estimates did not include all regions in England. Although the dataset remained nationally 
representative in terms of age and sex in 2019, and prevalence estimates of individual conditions 
were consistent with expectations, suggesting that national 2019 estimates are representative, 
regionally-stratified estimates in 2019 are incomplete. Prevalence estimates from 2014 include all 
regions but are less up-to-date, and differences from 2019 may reflect changes in prevalence and 
recording of conditions, and the CPRD GOLD population over time. Third, inclusion of individuals 
active in the dataset at any point between 1 January and 5 March could have resulted in some 
under-estimation of point prevalence on 5 March: sensitivity analysis suggested this was minimal. 
Finally, we were able to describe pregnancy in 2014 only, and pregnancy prevalence may be under-
estimated. 
Policy relevance 
We estimate that current national guidance on COVID-19 risk groups encompasses 18·5 million 
individuals across the UK, a larger population than previously estimated. 
Other studies have found that the health conditions in national COVID-19 guidance are indeed 
associated with increased risk of severe COVID-19, but to varying extents.3, 4 Older individuals are at 
higher risk of severe COVID-19 than younger, independent of underlying health conditions.3, 4  
Implementation of public health measures such as influenza vaccination generally achieve higher 
uptake when targeted on the basis of age rather than health conditions.25 We found that 66·2% of 
individuals aged ≥70 years had at least one recorded underlying condition, suggesting that an age-
based approach to COVID-19 vaccination could efficiently target individuals at highest risk. Age-
based vaccination strategies may also be more feasible to implement in low-resource settings. 
Our finding that 8·3% of school-aged children and 19·6% of working aged adults are in the at-risk 
population (as currently defined) emphasises the need to consider younger at-risk individuals in 
shielding guidance and when reopening schools and workplaces. The large number of children and 
younger adults with underlying conditions, who may nevertheless be at low absolute risk of severe 
COVID-19, supports vaccine strategies based on age- and condition-specific estimates of risk of 
severe COVID-19, rather than including individuals of any age with underlying conditions. We 
provide age-stratified prevalence for each condition to support effective vaccine resource allocation 
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Tables and Figures 
Box 1: The COVID-19 moderate- and high-risk population defined in national guidance1 compared to the at-risk study population  
COVID-19 moderate- and high-risk population definitions in national guidance for England1 Study definition of the at-risk 
population  
Anyone aged 70 years or older (regardless of medical conditions) is defined as at moderate risk. The study definition of the at-risk 
population for all ages comprised 
individuals with any of the 
underlying health conditions in 
national guidance, incorporating 
high risk groups as indicated. 
 
Detailed inclusion criteria for each 
condition were based on national 
guidance defining influenza clinical 
risk groups, to reflect risk of 
respiratory infection.26 
Among individuals aged less than 70 years, people at moderate risk from coronavirus infection include people 
who: 
• have a lung condition that’s not severe (such as asthma, COPD, emphysema or bronchitis) 
o high risk have been told by a doctor they have a severe lung condition (such as cystic fibrosis, 
severe asthma or severe COPD) 
• have heart disease (such as heart failure) 
• have diabetes 
• have chronic kidney disease 
• have liver disease (such as hepatitis) 
• have a condition affecting the brain or nerves (such as Parkinson’s disease, motor neurone disease, 
multiple sclerosis or cerebral palsy) 
• have a condition that means they have a high risk of getting infections 
o high risk have a condition that means they have a very high risk of getting infections (such as 
SCID or sickle cell) 
o high risk have blood or bone marrow cancer (such as leukaemia, lymphoma or myeloma) 
• are taking medicine that can affect the immune system (such as low doses of steroids) 
o high risk are taking medicine that makes them much more likely to get infections (such as high 
doses of steroids or immunosuppressant medicine) 
o high risk have had an organ transplant 
o high risk are having chemotherapy or antibody treatment for cancer, including immunotherapy 
o high risk are having an intense course of radiotherapy (radical radiotherapy) for lung cancer 
o high risk are having targeted cancer treatments that can affect the immune system (such as 
protein kinase inhibitors or PARP inhibitors) 
o high risk have had a bone marrow or stem cell transplant in the past 6 months, or are still 
taking immunosuppressant medicine 
• are very obese (a BMI of 40 or above) 
• are pregnant 
o high risk have a serious heart condition and are pregnant 
The prevalence of pregnancy, with 
and without any underlying health 
condition, was estimated separately 
from the general at-risk population. 
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Table 1: Study population characteristics and point prevalence of the COVID-19 at-risk population on 5 March 2019 in the United Kingdom using standalone primary care 
data, N=2,706,053 
  Scotland Northern Ireland Wales England  
  N=801,352 N=205,092 N=708,670 N=990,939 
  n Point prevalence 
/100,000 (95% CI) 
n Point prevalence 
/100,000 (95% CI) 
n Point prevalence 
/100,000 (95% CI) 
n Point prevalence 
/100,000 (95% CI) 
Demographics Mean age (SD)  42.3 (22.6)  40.7 (22.7)  42.6 (23.2)  40.8 (22.8) 
Female 403,151 50,309 (50,199–50,418) 102,545 50,000 (49,783–50,216) 356,080 50,246 (50,130–50,363) 496,988 50,153 (50,055–50,252) 
Ethnicity                 
  White 427,954 53,404 (53,295–53,513) 55,293 26,960 (26,768–27,153) 226,425 31,951 (31,842–32,059) 570,706 57,592 (57,495–57,690) 
  South Asian 9,325 1,164 (1,140–1,187) 764 373 (347–400) 7,440 1,050 (1,026–1,074) 48,334 4,878 (4,835–4,920) 
  Black 3,989 498 (482–513) 335 163 (146–182) 2,861 404 (389–419) 27,947 2,820 (2,788–2,853) 
  Other 9,360 1,168 (1,145–1,192) 1,102 537 (506–570) 4,497 635 (616–653) 20,106 2,029 (2,001–2,057) 
  Mixed 2,323 290 (278–302) 253 123 (109–140) 2,219 313 (300–326) 12,376 1,249 (1,227–1,271) 







Chronic liver disease 4,125 515 (499–531) 681 332 (308–358) 2,150 303 (291–316) 2,525 255 (245–265) 
Chronic heart disease 39,804 4,967 (4,920–5,015) 9,740 4,749 (4,657–4,842) 34,459 4,862 (4,813–4,913) 37,040 3,738 (3,701–3,775) 
Chronic respiratory disease (other 
than asthma) 
28,529 3,560 (3,520–3,601) 7,846 3,826 (3,743–3,910) 24,192 3,414 (3,372–3,456) 26,821 2,707 (2,675–2,739) 
Current asthma (only) 47,164 5,886 (5,834–5,937) 14,636 7,136 (7,025–7,249) 51,783 7,307 (7,247–7,368) 61,762 6,233 (6,185–6,280) 
Chronic neurological disease 29,631 3,698 (3,656–3,739) 6,729 3,281 (3,204–3,359) 23,850 3,365 (3,324–3,408) 27,488 2,774 (2,742–2,806) 
Diabetes mellitus 54,987 6,862 (6,807–6,917) 15,878 7,742 (7,627–7,858) 59,995 8,466 (8,401–8,531) 61,925 6,249 (6,202–6,297) 
Organ transplant recipient 748 93 (87–100) 182 89 (76–103) 653 92 (85–99) 894 90 (84–96) 
Asplenia/sickle cell disease 1,062 133 (125–141) 244 119 (105–135) 905 128 (120–136) 1,337 135 (128–142) 
Other immunosuppression  7,199 898 (878–919) 1,616 788 (750–827) 4,181 590 (572–608) 6,419 648 (632–664) 
Chronic kidney disease 54,845 6,844 (6,789–6,900) 17,296 8,433 (8,313–8,554) 53,280 7,518 (7,457–7,580) 69,894 7,053 (7,003–7,104) 







At-risk population1 196,378 24,506 (24,412–24,600) 53,945 26,303 (26,112–26,494) 187,695 26,486 (26,383–26,588) 223,587 22,563 (22,481–22,646) 
     among those aged <70 years 126,695 18,189 (18,098–18,279) 36,178 20,027 (19,843–20,213) 117,628 19,502 (19,402–19,602) 143,305 16,543 (16,464–16,621) 
     among those aged ≥70 years 69,683 66,498 (66,212–66,784) 17,767 72,670 (72,106–73,228) 70,067 66,405 (66,119–66,690) 80,282 64,401 (64,135–64,667) 




















































Multimorbidity2 58,076 7,247 (7,191–7,304) 16,248 7,922 (7,806–8,040) 55,556 7,839 (7,777–7,902) 60,994 6,155 (6,108–6,203) 
Cancer 
survivors 
Incident cancer in previous year 3,439 429 (415–444) 899 438 (410–468) 3,164 446 (431–462) 3,742 376 (364–388) 
Incident cancer in previous 5 years 12,847 1,603 (1,576–1,631) 3,344 1,630 (1,576–1,686) 12,451 1,757 (1,726–1,788) 14,663 1,480 (1,456–1,504) 
SD, standard deviation; 95% CI, 95% confidence interval; BMI, body mass index. 
1. The clinically vulnerable population comprised individuals with: any history of chronic respiratory disease other than asthma, heart disease, kidney disease, neurological conditions such as multiple sclerosis, diabetes mellitus; or with current 
asthma, severe obesity, or immunosuppression; assessed at each index date. 
2. Multimorbidity was defined as more than one condition among the following domains: asthma or other chronic respiratory disease; chronic heart disease; chronic kidney disease; chronic liver disease; chronic neurological disease; diabetes; or 
immunosuppression (including individuals with dysplenia and organ transplant recipients). 
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Table 2: Estimated size of the at-risk population in 2019 based on either age (≥ 70 years) or underlying health conditions among individuals aged 2 to 69 
years  
 Age 2 to 69 years Age 70 years or older Estimated total 
number of 




prevalence of at least 
one underlying health 
condition /100,000  
(95% CI) 




Estimated number of individuals aged 
2–69 years with at least one 
underlying health condition  
(95% CI) 
Office for National 
Statistics mid-2019 
population estimate 
Scotland 18,046 (17,956–18,137) 4,615,093 832,848 (828,694–837,019) 744,701 1,577,549 
Northern Ireland 19,672 (19,490–19,855) 1,622,687 319,213 (316,266–322,182) 224,851 544,064 
Wales 19,519 (19,418–19,619) 2,609,759 509,389 (506,776–512,011) 480,234 989,623 
England 16,573 (16,495–16,652) 47,467,071 7,866,870 (7,829,660–7,904,217) 7,556,976 15,423,846 
95% CI, 95% confidence interval 
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Among all women aged 11–49 years n 
Point prevalence 
/100,000 (95% CI) 
n 




/100,000 (95% CI) 
n 
Point prevalence 
/100,000 (95% CI) 
Pregnant or any underlying health 
condition1 
34,051 16,566 (16,406–16,728) 9,234 16,620 (16,311–16,932) 31,140 17,552 (17,376–17,730) 117,680 15,832 (15,749–15,915) 
Any underlying health condition1 31,389 15,271 (15,116–15,428) 8,317 14,970 (14,674–15,269) 28,733 16,196 (16,024–16,368) 102,121 13,738 (13,660–13,817) 
Pregnant 3,067 1,492 (1,440–1,545) 1,069 1,924 (1,811–2,042) 2,834 1,597 (1,540–1,657) 17,755 2,389 (2,354–2,424) 
Prevalence of underlying health conditions, stratified by pregnancy status among women aged 11–49 years 
Pregnant with an underlying health 
condition 
405 13,205 (12,026–14,455) 152 14,219 (12,179–16,458) 427 15,067 (13,769–16,458) 2,196 12,368 (11,887–12,862) 
Not pregnant, with an underlying 
health condition 
30,984 15,303 (15,146–15,460) 8,165 14,984 (14,686–15,287) 28,306 16,214 (16,041–16,388) 99,925 13,772 (13,693–13,851) 
95% CI, 95% confidence interval 
1. Underlying health conditions comprised: any history of chronic respiratory disease other than asthma, heart disease, kidney disease, neurological conditions such as multiple sclerosis, diabetes mellitus; or current 
asthma, severe obesity, or immunosuppression; assessed at each index date. 
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Table 4: Prevalence estimates for England with and without linked secondary care data in 2014 (N=1,802,468) and 2019 (N=744,496) 
  
Individuals in England eligible for secondary care data 
linkage in 2014 N=1,802,468 
Individuals in England eligible for secondary care data linkage 
in 2019 N=744,496 
Standalone primary care data  
Both primary and secondary 
care data 
Standalone primary care data  




/100,000 (95% CI) 
N 
Point prevalence 
/100,000 (95% CI) 
n 
Point prevalence 
/100,000 (95% CI) 
n 
Point prevalence 
/100,000 (95% CI) 
Underlying health conditions contributing to the at-risk population 
Chronic liver disease 4,499 250 (242–257) 8,104 450 (440–459) 2,022 272 (260–284) 3,941 529 (513–546) 
Chronic heart disease 87,217 4,839 (4,807–4,870) 108,711 6,031 (5,997–6,066) 29,399 3,949 (3,905–3,993) 39,083 5,250 (5,199–5,300) 
Chronic respiratory disease  53,358 2,960 (2,936–2,985) 63,562 3,526 (3,500–3,553) 21,345 2,867 (2,829–2,905) 26,407 3,547 (3,505–3,589) 
Current asthma (only) 125,548 6,965 (6,928–7,003) 136,702 7,584 (7,546–7,623) 48,009 6,449 (6,393–6,505) 53,030 7,123 (7,065–7,182) 
Chronic neurological disease 60,482 3,356 (3,329–3,382) 69,932 3,880 (3,852–3,908) 21,818 2,931 (2,892–2,969) 26,284 3,530 (3,489–3,573) 
Diabetes mellitus 110,144 6,111 (6,076–6,146) 114,149 6,333 (6,297–6,369) 48,461 6,509 (6,453–6,566) 50,760 6,818 (6,761–6,876) 
Organ transplant recipient 1,470 82 (77–86) 1,732 96 (92–101) 707 95 (88–102) 838 113 (105–120) 
Asplenia/sickle cell disease 2,545 141 (136–147) 2,878 160 (154–166) 1,089 146 (138–155) 1,346 181 (171–191) 
Other immunosuppression  14,134 784 (771–797) 32,537 1,805 (1,786–1,825) 5,035 676 (658–695) 7,663 1,029 (1,006–1,052) 
Chronic kidney disease 159,241 8,835 (8,793–8,876) 159,379 8,842 (8,801–8,884) 54,661 7,342 (7,283–7,401) 54,774 7,357 (7,298–7,417) 
Severe obesity (BMI ≥40 kg/m2) 36,668 2,581 (2,555–2,607) 36,668 2,581 (2,555–2,607) 16,706 2,898 (2,855–2,942) 16,706 2,898 (2,855–2,942) 
At-risk population 
At-risk population1 450,601 24,999 (24,936–25,062) 483,071 26,801 (26,736–26,865) 175,420 23,562 (23,466–23,659) 188,716 25,348 (25,249–25,447) 
   among those aged <70 years 276,158 17,756 (17,696–17,816) 303,528 19,516 (19,453–19,578) 112,168 17,286 (17,194–17,378) 123,038 18,961 (18,866–19,057) 
   among those aged ≥70 years 174,443 70,579 (70,399–70,759) 179,543 72,643 (72,466–72,818) 63,252 66,157 (65,856–66,457) 65,678 68,694 (68,399–68,988) 
Multimorbidity2 133,803 7,423 (7,385–7,462) 155,802 8,644 (8,603–8,685) 48,009 6,449 (6,393–6,505) 56,827 7,633 (7,573–7,693) 
Cancer survivors 
Incident cancer in previous year 8,343 463 (453–473) 10,680 593 (581–604) 2,936 394 (380–409) 3,806 511 (495–528) 
Incident cancer in previous 5 
years 
31,195 1,731 (1,712–1,750) 36,815 2,042 (2,022–2,063) 11,708 1,573 (1,544–1,601) 13,854 1,861 (1,830–1,892) 
95% CI, 95% confidence interval 
1. The clinically vulnerable population comprised individuals with: any history of chronic respiratory disease other than asthma, heart disease, kidney disease, neurological conditions such as multiple sclerosis, 
diabetes mellitus; or with current asthma, severe obesity, or immunosuppression; assessed at each index date. 
2. Multimorbidity was defined as more than one condition among the following domains: asthma or other chronic respiratory disease; chronic heart disease; chronic kidney disease; chronic liver disease; chronic 
neurological disease; diabetes; or immunosuppression (including individuals with dysplenia and organ transplant recipients).
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Figure 2: Age distributions of the at-risk population and common contributing underlying health conditions on 5 March 2019, N=2,706,053 
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Figure 4: Point prevalence of the at-risk population by region in England comparing 5 March 2014 (N=4,730,254) and 5 March 2019 (N=2,706,053) 
2019 study population did not include any individuals in the North East or East Midlands regions; x-axis scale starts at 20,000/100,000. 
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